Table 3. Compare the clinical performance characteristics of different screening strategies in the cervical high-grade lesions.
| Strategy | Strategy I | Strategy II | Strategy III | |
|---|---|---|---|---|
| CIN2+ | ||||
| Sensitivity | 91.08 (89.39–92.78) | 83.00 (80.76–85.23) | 90.99 (89.29–92.69) | |
| Specificity | 91.85 (91.47–92.22) | 94.10 (93.77–94.42) | 91.53 (89.29–92.69) | |
| PPV | 37.24 (35.40–39.08) | 42.76 (40.65–44.87) | 40.31 (38.37–42.25) | |
| NPV | 99.49 (99.39–99.59) | 99.05 (98.91–99.19) | 99.49 (99.39–99.59) | |
| Misdiagnosis | 8.92 (7.22–10.61) | 17.00 (14.77–19.24) | 8.01 (7.01–10.71) | |
| CIN3+ | ||||
| Sensitivity | 91.59 (90.19–90.99) | 88.77 (86.49–91.05) | 91.57 (91.19–91.95) | |
| Specificity | 94.86 (93.27–96.45) | 93.01 (92.67–93.36) | 94.72 (93.11–96.33) | |
| PPV | 26.34 (24.67–28.02) | 31.06 (29.09–33.03) | 28.50 (26.72–30.29) | |
| NPV | 99.80 (99.74–99.86) | 99.57 (99.48–99.66) | 99.80 (99.73–99.86) | |
| Misdiagnosis | 5.14 (3.55–6.73) | 11.23 (8.95–13.51) | 5.02 (3.67–6.89) | |
Data were presented as number of patients/total patients (%, 95% CI).
CI, confidence interval; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; NPV, negative predictive value; PPV, positive predictive value.